ClinicalTrials.gg
CompletedNCT02879305Updated Dec 3, 2021Results posted

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

A Phase 3 interventional study of Daprodustat and rhEPO in Anaemia and Aspergillosis, Allergic Bronchopulmonary, sponsored by GlaxoSmithKline. Completed at 462 sites in 35 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,964
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
2nd of 30
2,964 · median 76
Started
2016
with 4 others
Phase 3
9 of 30
1 open now
Registered
17th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 2nd largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 3, and was the 17th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.

03

Conditions studied

  • Anaemia
  • Aspergillosis, Allergic Bronchopulmonary

Keywords

  • erythropoiesis stimulating agents
  • GSK1278863
  • daprodustat
  • anemia
  • chronic kidney disease
  • hemoglobin
  • recombinant human erythropoietin
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 to 99 years of age (inclusive).
  • Erythropoietin-stimulating agents (ESAs): Use of any approved ESA for at least the 6 weeks prior to screening and between screening and randomization.
  • concentration: On Week -8: Hgb 8 to 12 grams per deciliter (g/dL). On randomization (Day 1): Hgb 8 to 11 g/dL and receiving at least the minimum ESA dose. Hgb >11 g/dL to 11.5 g/dL and receiving greater than the minimum ESA dose.
  • Dialysis: On dialysis >90 days prior to screening and continuing on the same mode of dialysis from screening (Week -8) through to randomization (Day 1).
  • Frequency of Dialysis: Hemodialysis (HD) >=2 times/week and peritoneal dialysis (PD) >=5 times/week. Home hemodialysis >=2 times/week.
  • Compliance with placebo [randomization (Day 1) only]: >=80% and \<=120% compliance with placebo during run-in period.
  • (screening only): capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Kidney transplant: Planned living-related or living-unrelated kidney transplant within 52 weeks after study start (Day 1).
  • Ferritin: \<=100 nanograms (ng)/milliliter (mL) (\<=100 micrograms/liter [L]) at screening.
  • Transferrin saturation (TSAT) (screening only): \<=20%.
  • Aplasias: History of bone marrow aplasia or pure red cell aplasia.
  • Other causes of anemia: Untreated Pernicious anemia, thalassemia major, sickle cell disease or myelodysplastic syndrome.
  • Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or GI bleeding \<=4 weeks prior to screening through to randomization (Day 1).
  • MI or acute coronary syndrome: \<=4 weeks prior to screening through to randomization (Day 1).
  • Stroke or : \<=4 weeks prior to screening through to randomization (Day 1).
  • Heart failure (HF): Chronic Class IV HF, as defined by the (NYHA) functional classification system.
  • Current uncontrolled hypertension: Current uncontrolled hypertension as determined by the investigator that would contraindicate the use of recombinant human erythropoietin (rhEPO).
  • Bazett's interval (QTcB) (Day 1): QTcB >500 millisecond (msec), or QTcB >530 msec in subjects with bundle branch block. There is no QT Interval Corrected for Heart Rate (QTc) exclusion for subjects with a predominantly ventricular paced rhythm.
  • (ALT): >2x (ULN) at screening.
  • : >1.5xULN at screening.
  • Current unstable liver or biliary disease per investigator assessment, generally defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • : History of malignancy within the 2 years prior to screening through to randomization (Day 1) or currently receiving treatment for cancer, or complex kidney cyst (example [e.g.] Bosniak Category II F, III or IV) > 3 centimeter (cm); with the exception of localized squamous cell or basal cell carcinoma of the skin that has been definitively treated >=4 weeks prior to screening.
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to in the product, or epoetin alfa or darbepoetin alfa.
  • Drugs and supplements: Use of strong inhibitors of Cytochrome P4502C8 (CYP2C8) (e.g., gemfibrozil) or strong inducers of CYP2C8 (e.g., rifampin/rifampicin).
  • Other study participation: Use of other investigational agent or device prior to screening through to randomization (Day 1).
  • Prior treatment with daprodustat: Any prior treatment with daprodustat for treatment duration of >30 days.
  • Females only: Subject is pregnant [as confirmed by a positive serum human chorionic gonadotrophin (hCG) test for females of (FRP) only], subject is breastfeeding, or subject is of reproductive potential and does not agree to follow one of the options listed in the List of Highly Effective Methods for Avoiding Pregnancy.
  • Other Conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the subject at unacceptable risk, which may affect study compliance (e.g., intolerance to rhEPO) or prevent understanding of the aims or investigational procedures or possible consequences of the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,964 participants (actual)

Study arms

  • Experimental
    Daprodustat

    Participants will receive oral daprodustat once daily.

    Drug: Daprodustat · Drug: Placebo · Drug: Iron therapy

  • Active comparator
    rhEPO

    Participants on peritoneal dialysis (PD) will be administered darbepoetin alfa subcutaneously (SC) and participants on hemodialysis (HD) will be administered epoetin alfa intravenously (IV).

    Drug: rhEPO · Drug: Placebo · Drug: Iron therapy

Interventions

  • Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.

  • DrugrhEPO

    The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.

  • DrugPlacebo

    Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

  • DrugIron therapy

    Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis

    Time to MACE defined as the time to first occurrence of Clinical Events Committee (CEC) adjudicated MACE (composite of all-cause mortality, non-fatal myocardial infarction \[MI\] and non-fatal stroke) was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) plus (+) 1. The incidence rate per 100 person years calculated as (100 multiplied by \[\*\] number of participants with at least 1 event) divided by \[/\] first event person-years) is presented along with 95 percent (%) confidence interval (CI). First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  2. Mean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52)

    Blood samples were collected from participants for hemoglobin measurements. Hemoglobin during the evaluation period was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis, missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputation methods. Change from Baseline was defined as post-Baseline value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)

Secondary outcomes

  1. Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period: Superiority Analysis

    Time to MACE defined as the time to first occurrence of CEC adjudicated MACE was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariate. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  2. Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated MACE or thromboembolic event (vascular access thrombosis, symptomatic deep vein thrombosis or symptomatic pulmonary embolism) was analyzed using a Cox proportional hazards regression model with with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  3. Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated MACE or hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  4. Mean Average Monthly On-treatment IV Iron Dose Per Participant

    Average monthly IV iron dose (milligrams) per participant from Day 1 to Week 52 was determined by calculating the total IV iron dose per participant from treatment start date + 1 to the earliest of (Week 52 visit date, first blood (red blood cell \[RBC\] or whole blood) transfusion date, and treatment stop date + 1 day) which corresponds to the time while the participant was on randomized treatment and before receiving a blood transfusion. This total IV iron dose was divided by (the number of days from treatment start date + 1 to the earliest of (Week 52 visit date, first blood transfusion date (RBC or whole blood), and treatment stop date +1) / 30.4375 days). This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

    Time frame: Day 1 to Week 52

  5. Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period

    Time to first occurrence of adjudicated all-cause mortality was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the vital status for follow-up time period.

    Time frame: Up to 3.9 person-years for vital status follow-up time period

  6. Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated CV mortality was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  7. Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated MI (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  8. Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated stroke (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  9. Number of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)

    Number of participants with adjudicated MACE or hospitalization for heart failure (recurrent events analysis) is presented, categorized by number of occurrences of adjudicated MACE or hospitalization for heart failure per participant.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  10. Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated CV mortality or non-fatal MI was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  11. Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period

    All-cause hospitalization events were hospital admissions recorded on the Hospitalization electronic case report form (eCRF) with a hospitalization duration \>=24 hours. Time to first occurrence of all-cause hospitalization was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  12. Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period

    All-cause hospital re-admissions within 30days are defined as hospital admissions recorded on hospitalization eCRF with hospitalization duration of \>=24 hours and admission date within 30days following previous discharge date of all-cause hospitalization event, where previous hospitalization was \>=24 hours. Time to first occurrence of all-cause hospital re-admission within 30days was analyzed using Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. Incidence rate per 100person years calculated as(100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  13. Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated MACE or hospitalization for heart failure or thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  14. Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  15. Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 3.9 person-years for CV follow-up time period

  16. Change From Baseline in Post-randomization Hemoglobin Levels at Week 52

    Blood samples were collected from participants for hemoglobin measurements. Change from Baseline was defined as post-Baseline value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using mixed model repeated measures (MMRM) model fitted from Baseline up to Week 52, excluding values collected during the stabilization period, with factors for treatment, time, dialysis type, region, Baseline hemoglobin and Baseline hemoglobin by time and treatment by time interactions.

    Time frame: Baseline (Pre-dose on Day 1) and Week 52

  17. Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)

    Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hemoglobin responders were defined as participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.

    Time frame: Week 28 to Week 52

  18. Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].

    Time frame: Week 28 to Week 52

  19. Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].

    Time frame: Week 28 to Week 52

  20. Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].

    Time frame: Week 28 to end of study (3.9 person-years for follow-up time period)

  21. Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].

    Time frame: Week 28 to end of study (3.9 person-years for follow-up time period)

  22. Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52

    SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is the average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using MMRM model with treatment group + time + dialysis type + region + Baseline value + Baseline value\*time + treatment group\*time, using an unstructured covariance matrix. Data for post-dialysis BP measurements have been presented.

    Time frame: Baseline (Week -4) and Week 52

  23. Change From Baseline in SBP, DBP, MAP at End of Treatment

    SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using ANCOVA model with terms for treatment group, dialysis type, region and Baseline value. Data for post-dialysis BP measurements have been presented.

    Time frame: Baseline (Week -4) and 45.1 months

  24. Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years

    BP exacerbation was defined (based on post-dialysis) as: SBP \>= 25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the negative binomial model with treatment, dialysis type and region as covariates and the logarithm of time on-treatment as an offset variable. Data for post-dialysis BP measurements have been presented.

    Time frame: Day 1 to end of study (3.9 person-years for follow-up time period)

  25. Number of Participants With at Least One BP Exacerbation Event During Study

    BP exacerbation was defined as: SBP \>= 25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one BP exacerbation event is presented.

    Time frame: Day 1 to end of study (3.9 person-years for follow-up time period)

  26. Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria

    Percentage of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.

    Time frame: Day 1 to 45.1 months

  27. Change From Baseline in On-Treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  28. Change From Baseline in On-Treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  29. Change From Baseline in On-Treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain, general health, mental health, role-emotional (role limitations caused by emotional problems), role-physical (role limitations caused by physical problems), social functioning (Social fun), physical functioning (Phy. fun) and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  30. Change From Baseline in On-Treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  31. Change From Baseline in On-Treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  32. Change From Baseline in On-Treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52

    EQ-5D-5L is self-assessment questionnaire,consisting of 5 items covering 5 dimensions (mobility,self care,usual activities,pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health state). Change from Baseline was calculated as on-treatment visit value-Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.

    Time frame: Baseline (Pre-dose on Day 1) and Week 52

  33. Change From Baseline in On-Treatment EuroQol Visual Analogue Scale (EQ-VAS) at Week 52

    The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst health one can imagine and 100 represents the best health one can imagine. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1) and Week 52

  34. Change From Baseline in On-Treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52

    The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated worse outcome. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

07

Results

Posted Dec 3, 2021

Participant flow

This was a randomized, open-label (sponsor blind), active-controlled, parallel-group, event-driven study conducted at 431 centers in 35 countries. Participants were randomized to receive daprodustat and recombinant human erythropoietin (rhEPO) (epoetin alfa or darbepoetin alfa).

Participant flow — Overall Study
MilestoneDaprodustatrhEPO
Started14871477
Completed13701366
Not completed117111
Withdrew: Investigator site closed5557
Withdrew: Withdrawal by subject4442
Withdrew: Lost to follow-up1712
Withdrew: Other10

Outcome measures

PrimaryTime to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis

Time to MACE defined as the time to first occurrence of Clinical Events Committee (CEC) adjudicated MACE (composite of all-cause mortality, non-fatal myocardial infarction \[MI\] and non-fatal stroke) was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) plus (+) 1. The incidence rate per 100 person years calculated as (100 multiplied by \[\*\] number of participants with at least 1 event) divided by \[/\] first event person-years) is presented along with 95 percent (%) confidence interval (CI). First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis11.07 (9.98 to 12.26)11.86 (10.72 to 13.09)
Statistical analysis
  • Daprodustat vs rhEPO · Hazard ratio (hr): 0.93 · 95% CI 0.81 to 1.07Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
PrimaryMean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52)

Blood samples were collected from participants for hemoglobin measurements. Hemoglobin during the evaluation period was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis, missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputation methods. Change from Baseline was defined as post-Baseline value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Reported as:
Least squares mean · Grams per deciliter
Mean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52)
Grams per deciliterDaprodustatrhEPO
Mean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52)0.28 ± 0.0220.10 ± 0.022
Statistical analysis
  • Daprodustat vs rhEPO · Least square (ls) mean difference: 0.18 · 95% CI 0.12 to 0.24Analysis of covariance (ANCOVA) model adjusted for treatment, Baseline Hgb, dialysis type and region along with 95% CI for treatment difference (daprodustat-rhEPO).
SecondaryTime to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period: Superiority Analysis

Time to MACE defined as the time to first occurrence of CEC adjudicated MACE was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariate. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period: Superiority Analysis
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period: Superiority Analysis11.07 (9.98 to 12.26)11.86 (10.72 to 13.09)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.156123 (The p-value was compared against 0.0125 based on the Holm-Bonferonni adjustment.) · Hazard ratio (hr): 0.93 · 95% CI 0.81 to 1.07Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period

Time to first occurrence of adjudicated MACE or thromboembolic event (vascular access thrombosis, symptomatic deep vein thrombosis or symptomatic pulmonary embolism) was analyzed using a Cox proportional hazards regression model with with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period15.84 (14.48 to 17.30)17.85 (16.38 to 19.42)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.023539 (The p-value was compared against 0.006250 based on the Holm-Bonferonni adjustment.) · Hazard ratio (hr): 0.88 · 95% CI 0.78 to 1.00Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period

Time to first occurrence of adjudicated MACE or hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period12.98 (11.77 to 14.27)13.38 (12.15 to 14.70)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.325797 (The p-value was compared against 0.025000 based on the Holm-Bonferonni adjustment.) · Hazard ratio (hr): 0.97 · 95% CI 0.85 to 1.11Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryMean Average Monthly On-treatment IV Iron Dose Per Participant

Average monthly IV iron dose (milligrams) per participant from Day 1 to Week 52 was determined by calculating the total IV iron dose per participant from treatment start date + 1 to the earliest of (Week 52 visit date, first blood (red blood cell \[RBC\] or whole blood) transfusion date, and treatment stop date + 1 day) which corresponds to the time while the participant was on randomized treatment and before receiving a blood transfusion. This total IV iron dose was divided by (the number of days from treatment start date + 1 to the earliest of (Week 52 visit date, first blood transfusion date (RBC or whole blood), and treatment stop date +1) / 30.4375 days). This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

Time frame:
Day 1 to Week 52
Reported as:
Least squares mean · Milligrams
Mean Average Monthly On-treatment IV Iron Dose Per Participant
MilligramsDaprodustatrhEPO
Mean Average Monthly On-treatment IV Iron Dose Per Participant90.8 ± 3.3499.9 ± 3.35
Statistical analysis
  • Daprodustat vs rhEPO · ANCOVA · p = 0.026947 (The p-value was compared against 0.008333 based on the Holm-Bonferonni adjustment.) · Ls mean difference: -9.1 · 95% CI -18.4 to 0.2Analysis was carried out by using ANCOVA model with terms for treatment, Baseline monthly IV iron dose, dialysis type and region.
SecondaryTime to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period

Time to first occurrence of adjudicated all-cause mortality was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the vital status for follow-up time period.

Time frame:
Up to 3.9 person-years for vital status follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period8.32 (7.39 to 9.32)8.59 (7.65 to 9.62)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.3281 · Hazard ratio (hr): 0.96 · 95% CI 0.82 to 1.13Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period

Time to first occurrence of adjudicated CV mortality was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period3.31 (2.74 to 3.97)3.46 (2.88 to 4.14)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.3553 · Hazard ratio (hr): 0.95 · 95% CI 0.74 to 1.23Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period

Time to first occurrence of adjudicated MI (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period3.34 (2.76 to 4.01)4.08 (3.43 to 4.83)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.0524 · Hazard ratio (hr): 0.81 · 95% CI 0.63 to 1.04Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period

Time to first occurrence of adjudicated stroke (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period1.23 (0.89 to 1.66)1.48 (1.10 to 1.94)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.1927 · Hazard ratio (hr): 0.84 · 95% CI 0.56 to 1.25Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryNumber of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)

Number of participants with adjudicated MACE or hospitalization for heart failure (recurrent events analysis) is presented, categorized by number of occurrences of adjudicated MACE or hospitalization for heart failure per participant.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Count of participants · Participants
Number of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)
ParticipantsDaprodustatrhEPO
Occurrences per participant: 010621044
Occurrences per participant: 1315300
Occurrences per participant: 27288
Occurrences per participant: 32522
Occurrences per participant: 4311
Occurrences per participant: 544
Occurrences per participant: 643
Occurrences per participant: 702
Occurrences per participant: 801
Occurrences per participant: 911
Occurrences per participant: 1011
Statistical analysis
  • Daprodustat vs rhEPO · Chi-squared · p = 0.0351 · Hazard ratio (hr): 0.90 · 95% CI 0.80 to 1.01Overall HR is presented using Model 1. Model 1 assumed a common treatment effect, regardless of number of events experienced. HR was estimated using a Prentice, Williams and Peterson(PWP) model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs rhEPO · Chi-squared · p = 0.3258 · Hazard ratio (hr): 0.97 · 95% CI 0.85 to 1.11First Event Hazard ratio is presented using Model 2. Model 2 assumed treatment effect differs by number of events experienced. Hazard Ratio (HR) was estimated using a PWP model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs rhEPO · Chi-squared · p = 0.0158 · Hazard ratio (hr): 0.75 · 95% CI 0.58 to 0.98Second Event Hazard ratio is presented using Model 2. Model 2 assumed treatment effect differs by number of events experienced. HR was estimated using a PWP model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs rhEPO · Chi-squared · p = 0.0981 · Hazard ratio (hr): 0.74 · 95% CI 0.47 to 1.17Third Event Hazard ratio is presented using Model 2. Model 2 assumed treatment effect differs by number of events experienced. HR was estimated using a PWP model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs rhEPO · Chi-squared · p = 0.3258 · Hazard ratio (hr): 0.97 · 95% CI 0.85 to 1.11First Event Hazard ratio is presented using Model 3. Model 3 assumed treatment effect for first event differs from a common effect for subsequent events. HR was estimated using a PWP model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs rhEPO · Chi-squared · p = 0.0058 · Hazard ratio (hr): 0.75 · 95% CI 0.60 to 0.94Subsequent Event Hazard ratio is presented using Model 3. Model 3 assumed treatment effect for first event differs from a common effect for subsequent events. HR was estimated using a PWP model, with treatment, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period

Time to first occurrence of adjudicated CV mortality or non-fatal MI was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period5.98 (5.18 to 6.86)6.79 (5.94 to 7.73)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.0872 · Hazard ratio (hr): 0.88 · 95% CI 0.73 to 1.06Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period

All-cause hospitalization events were hospital admissions recorded on the Hospitalization electronic case report form (eCRF) with a hospitalization duration \>=24 hours. Time to first occurrence of all-cause hospitalization was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period43.92 (41.18 to 46.81)46.03 (43.17 to 49.04)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.1540 · Hazard ratio (hr): 0.95 · 95% CI 0.87 to 1.04Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period

All-cause hospital re-admissions within 30days are defined as hospital admissions recorded on hospitalization eCRF with hospitalization duration of \>=24 hours and admission date within 30days following previous discharge date of all-cause hospitalization event, where previous hospitalization was \>=24 hours. Time to first occurrence of all-cause hospital re-admission within 30days was analyzed using Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. Incidence rate per 100person years calculated as(100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period8.86 (7.85 to 9.95)9.67 (8.62 to 10.82)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.1244 · Hazard ratio (hr): 0.91 · 95% CI 0.77 to 1.07Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period

Time to first occurrence of adjudicated MACE or hospitalization for heart failure or thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period17.74 (16.28 to 19.30)19.50 (17.94 to 21.16)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.0540 · Hazard ratio (hr): 0.91 · 95% CI 0.81 to 1.02Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period

Time to first occurrence of adjudicated hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period3.30 (2.72 to 3.97)3.01 (2.45 to 3.65)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.7658 · Hazard ratio (hr): 1.10 · 95% CI 0.84 to 1.45Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period

Time to first occurrence of adjudicated thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 3.9 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatrhEPO
Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period5.66 (4.87 to 6.54)6.75 (5.88 to 7.72)
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.0425 · Hazard ratio (hr): 0.84 · 95% CI 0.69 to 1.02Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, dialysis type and region as covariates.
SecondaryChange From Baseline in Post-randomization Hemoglobin Levels at Week 52

Blood samples were collected from participants for hemoglobin measurements. Change from Baseline was defined as post-Baseline value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using mixed model repeated measures (MMRM) model fitted from Baseline up to Week 52, excluding values collected during the stabilization period, with factors for treatment, time, dialysis type, region, Baseline hemoglobin and Baseline hemoglobin by time and treatment by time interactions.

Time frame:
Baseline (Pre-dose on Day 1) and Week 52
Reported as:
Least squares mean · Grams per deciliter
Change From Baseline in Post-randomization Hemoglobin Levels at Week 52
Grams per deciliterDaprodustatrhEPO
Change From Baseline in Post-randomization Hemoglobin Levels at Week 520.26 ± 0.0320.14 ± 0.032
Statistical analysis
  • Daprodustat vs rhEPO · Ls mean difference: 0.12 · 95% CI 0.03 to 0.21
SecondaryNumber of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)

Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hemoglobin responders were defined as participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.

Time frame:
Week 28 to Week 52
Reported as:
Count of participants · Participants
Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)
ParticipantsDaprodustatrhEPO
Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)903866
Statistical analysis
  • Daprodustat vs rhEPO · Cochran-Mantel-Haenszel · p = 0.0367 · Difference in response rate: 3.5 · 95% CI -0.1 to 7.1Cochran-Mantel-Haenszel (CMH) test adjusted for dialysis type, and region was used to compare the number of responders between the treatment groups.
SecondaryPercentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].

Time frame:
Week 28 to Week 52
Reported as:
Median · Percentage of days
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis
Percentage of daysDaprodustatrhEPO
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis60.9 (0.0 to 100.0)59.4 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs rhEPO · Median difference (final values): 1.06 · 95% CI 0.00 to 3.86Hodges-Lehmann estimate of the treatment difference (daprodustat-rhEPO) and associated two-sided asymptotic 95% CI is presented.
SecondaryPercentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].

Time frame:
Week 28 to Week 52
Reported as:
Median · Percentage of days
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis
Percentage of daysDaprodustatrhEPO
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis60.9 (0.0 to 100.0)59.4 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs rhEPO · van Elteren test · p = 0.0805 · Probability: 0.52 · 95% CI 0.49 to 0.54Mann-Whitney estimate (Probability) of the treatment effect has been presented.
SecondaryPercentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].

Time frame:
Week 28 to end of study (3.9 person-years for follow-up time period)
Reported as:
Median · Percentage of days
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis
Percentage of daysDaprodustatrhEPO
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis60.9 (0.0 to 100.0)57.7 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs rhEPO · Median difference (final values): 2.18 · 95% CI 0.28 to 4.05Hodges-Lehmann estimate of the treatment difference (daprodustat-rhEPO) and associated two-sided asymptotic 95% CI is presented.
SecondaryPercentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].

Time frame:
Week 28 to end of study (3.9 person-years for follow-up time period)
Reported as:
Median · Percentage of days
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis
Percentage of daysDaprodustatrhEPO
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis60.9 (0.0 to 100.0)57.7 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs rhEPO · van Elteren test · p = 0.0139 · Probability: 0.53 · 95% CI 0.50 to 0.55Mann-Whitney estimate (Probability) of the treatment effect has been presented.
SecondaryChange From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52

SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is the average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using MMRM model with treatment group + time + dialysis type + region + Baseline value + Baseline value\*time + treatment group\*time, using an unstructured covariance matrix. Data for post-dialysis BP measurements have been presented.

Time frame:
Baseline (Week -4) and Week 52
Reported as:
Least squares mean · Millimeter of mercury
Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52
Millimeter of mercuryDaprodustatrhEPO
SBP-0.61 ± 0.582-0.93 ± 0.578
DBP-1.04 ± 0.326-0.58 ± 0.324
MAP-0.89 ± 0.370-0.71 ± 0.368
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.6551 · Ls mean difference: 0.33 · 95% CI -1.28 to 1.94The difference in change from Baseline in SBP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in means between arms.
  • Daprodustat vs rhEPO · MMRM · p = 0.1586 · Ls mean difference: -0.46 · 95% CI -1.36 to 0.44The difference in change from Baseline in DBP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in means between arms.
  • Daprodustat vs rhEPO · MMRM · p = 0.3646 · Ls mean difference: -0.18 · 95% CI -1.20 to 0.84The difference in change from Baseline in MAP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in means between arms.
SecondaryChange From Baseline in SBP, DBP, MAP at End of Treatment

SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using ANCOVA model with terms for treatment group, dialysis type, region and Baseline value. Data for post-dialysis BP measurements have been presented.

Time frame:
Baseline (Week -4) and 45.1 months
Reported as:
Least squares mean · Millimeter of mercury
Change From Baseline in SBP, DBP, MAP at End of Treatment
Millimeter of mercuryDaprodustatrhEPO
SBP-0.43 ± 0.554-0.43 ± 0.557
DBP-0.92 ± 0.310-1.37 ± 0.312
MAP-0.75 ± 0.350-1.06 ± 0.351
Statistical analysis
  • Daprodustat vs rhEPO · ANCOVA · p = 0.5012 · Ls mean difference: 0.00 · 95% CI -1.54 to 1.54For SBP: Treatment group comparisons were based on an ANCOVA model with terms for treatment group, dialysis type, region and Baseline value.
  • Daprodustat vs rhEPO · ANCOVA · p = 0.8451 · Ls mean difference: 0.45 · 95% CI -0.42 to 1.31For DBP: Treatment group comparisons were based on an ANCOVA model with terms for treatment group, dialysis type, region and Baseline value.
  • Daprodustat vs rhEPO · ANCOVA · p = 0.7312 · Ls mean difference: 0.31 · 95% CI -0.67 to 1.28For MAP: Treatment group comparisons were based on an ANCOVA model with terms for treatment group, dialysis type, region and Baseline value.
SecondaryBlood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years

BP exacerbation was defined (based on post-dialysis) as: SBP \>= 25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the negative binomial model with treatment, dialysis type and region as covariates and the logarithm of time on-treatment as an offset variable. Data for post-dialysis BP measurements have been presented.

Time frame:
Day 1 to end of study (3.9 person-years for follow-up time period)
Reported as:
Number · Events per 100 participant years
Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years
Events per 100 participant yearsDaprodustatrhEPO
Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years207.13 (188.83 to 227.21)206.38 (187.88 to 226.71)
Statistical analysis
  • Daprodustat vs rhEPO · Negative binomial model · p = 0.5290 · Ratio of exacerbation rate: 1.00 · 95% CI 0.91 to 1.11Ratio of model estimated exacerbation rates and CIs were estimated using a negative binomial model for the treatment group comparison.
SecondaryNumber of Participants With at Least One BP Exacerbation Event During Study

BP exacerbation was defined as: SBP \>= 25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one BP exacerbation event is presented.

Time frame:
Day 1 to end of study (3.9 person-years for follow-up time period)
Reported as:
Count of participants · Participants
Number of Participants With at Least One BP Exacerbation Event During Study
ParticipantsDaprodustatrhEPO
Number of Participants With at Least One BP Exacerbation Event During Study11911186
SecondaryPercentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria

Percentage of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.

Time frame:
Day 1 to 45.1 months
Reported as:
Number · Percentage of participants
Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria
Percentage of participantsDaprodustatrhEPO
Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria3.63.6
Statistical analysis
  • Daprodustat vs rhEPO · Wald test · p = 0.5772 · Hazard ratio (hr): 1.04 · 95% CI 0.71 to 1.52Hazard ratio was estimated using a Cox proportional hazard regression model adjusted for treatment group, dialysis type and region.
SecondaryChange From Baseline in On-Treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-Treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatrhEPO
Week 8, n=982,9360.30 ± 0.2050.01 ± 0.210
Week 12, n=990,9430.33 ± 0.203-0.27 ± 0.207
Week 28, n=836,819-0.23 ± 0.229-0.57 ± 0.232
Week 52, n=729,707-0.52 ± 0.248-1.05 ± 0.252
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.1620 · Ls mean difference: 0.29 · 95% CI -0.29 to 0.86Week 8: Model was fitted from Baseline up to Week 52 and the model adjusted Week 8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.0180 · Ls mean difference: 0.61 · 95% CI 0.04 to 1.18Week 12: Model was fitted from Baseline up to Week 52 and the model adjusted Week 12 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.1530 · Ls mean difference: 0.33 · 95% CI -0.31 to 0.97Week 28: Model was fitted from Baseline up to Week 52 and the model adjusted Week 28 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.0686 · Ls mean difference: 0.53 · 95% CI -0.17 to 1.22Week 52: Model was fitted from Baseline up to Week 52 and the model adjusted Week 52 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-Treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-Treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatrhEPO
Week 8, n=982,936-0.38 ± 0.254-0.21 ± 0.260
Week 12, n=990,943-0.55 ± 0.262-0.72 ± 0.268
Week 28, n=836,819-1.25 ± 0.286-1.23 ± 0.290
Week 52, n=729,707-1.63 ± 0.311-1.03 ± 0.316
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.6807 · Ls mean difference: -0.17 · 95% CI -0.88 to 0.54Week 8: Model was fitted from Baseline up to Week 52 and the model adjusted Week 8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.3256 · Ls mean difference: 0.17 · 95% CI -0.57 to 0.91Week 12: Model was fitted from Baseline up to Week 52 and the model adjusted Week 12 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.5144 · Ls mean difference: -0.01 · 95% CI -0.81 to 0.78Week 28: Model was fitted from Baseline up to Week 52 and the model adjusted Week 28 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.9120 · Ls mean difference: -0.60 · 95% CI -1.47 to 0.27Week 52: Model was fitted from Baseline up to Week 52 and the model adjusted Week 52 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-Treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain, general health, mental health, role-emotional (role limitations caused by emotional problems), role-physical (role limitations caused by physical problems), social functioning (Social fun), physical functioning (Phy. fun) and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-Treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatrhEPO
Bodily pain: Week 8, n=982,936-0.13 ± 0.2650.12 ± 0.272
Bodily pain: Week 12, n=990,9430.20 ± 0.267-0.39 ± 0.274
Bodily pain: Week 28, n=836,819-0.70 ± 0.297-0.74 ± 0.301
Bodily pain: Week 52, n=729,707-1.12 ± 0.313-1.39 ± 0.318
General health: Week 8, n=982,936-0.39 ± 0.208-0.65 ± 0.213
General health: Week 12, n=990,943-0.59 ± 0.210-1.04 ± 0.215
General health: Week 28, n=836,819-1.32 ± 0.232-0.99 ± 0.235
General health: Week 52, n=729,707-1.51 ± 0.251-1.22 ± 0.255
Mental health: Week 8, n=982,936-0.43 ± 0.238-0.47 ± 0.244
Mental health: Week 12, n=990,943-0.86 ± 0.247-0.81 ± 0.253
Mental health: Week 28, n=836,819-1.30 ± 0.267-1.43 ± 0.270
Mental health: Week 52, n=729,707-1.97 ± 0.296-1.16 ± 0.301
Role-emotional: Week 8, n=982,936-0.10 ± 0.310-0.02 ± 0.317
Role-emotional: Week 12, n=990,943-0.17 ± 0.311-0.53 ± 0.318
Role-emotional: Week 28, n=836,819-0.95 ± 0.335-0.90 ± 0.339
Role-emotional: Week 52, n=729,707-0.83 ± 0.358-0.92 ± 0.363
Role-physical: Week 8, n=982,9360.40 ± 0.2410.32 ± 0.246
Role-physical: Week 12, n=990,9430.48 ± 0.2390.08 ± 0.245
Role-physical: Week 28, n=836,819-0.10 ± 0.257-0.39 ± 0.260
Role-physical: Week 52, n=729,707-0.21 ± 0.285-0.60 ± 0.289
Social functioning: Week 8, n=982,9360.24 ± 0.2410.38 ± 0.247
Social functioning: Week 12, n=990,9430.25 ± 0.255-0.44 ± 0.261
Social functioning: Week 28, n=836,819-0.61 ± 0.280-0.94 ± 0.283
Social functioning: Week 52, n=729,707-1.12 ± 0.315-1.14 ± 0.320
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.7432 · Ls mean difference: -0.25 · 95% CI -0.99 to 0.50Bodily pain,Week8: Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.0631 · Ls mean difference: 0.58 · 95% CI -0.16 to 1.33Bodily pain,Week12: Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.4604 · Ls mean difference: 0.04 · 95% CI -0.79 to 0.87Bodily pain,Week28: Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.2688 · Ls mean difference: 0.28 · 95% CI -0.60 to 1.15Bodily pain,Week52: Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.1918 · Ls mean difference: 0.26 · 95% CI -0.32 to 0.84General health,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.0677 · Ls mean difference: 0.45 · 95% CI -0.14 to 1.04General health,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.8386 · Ls mean difference: -0.33 · 95% CI -0.98 to 0.32General health,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.7928 · Ls mean difference: -0.29 · 95% CI -0.99 to 0.41General health,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.4537 · Ls mean difference: 0.04 · 95% CI -0.63 to 0.71Mental health,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.5548 · Ls mean difference: -0.05 · 95% CI -0.74 to 0.65Mental health,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.3626 · Ls mean difference: 0.13 · 95% CI -0.61 to 0.88Mental health,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.9721 · Ls mean difference: -0.81 · 95% CI -1.64 to 0.02Mental health,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.5789 · Ls mean difference: -0.09 · 95% CI -0.96 to 0.78Role-emotional,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.2054 · Ls mean difference: 0.37 · 95% CI -0.51 to 1.24Role-emotional,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.5389 · Ls mean difference: -0.05 · 95% CI -0.98 to 0.89Role-emotional,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.4289 · Ls mean difference: 0.09 · 95% CI -0.91 to 1.09Role-emotional,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.4096 · Ls mean difference: 0.08 · 95% CI -0.60 to 0.75Role-physical,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.1196 · Ls mean difference: 0.40 · 95% CI -0.27 to 1.07Role-physical,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions
  • Daprodustat vs rhEPO · MMRM · p = 0.2093 · Ls mean difference: 0.30 · 95% CI -0.42 to 1.01Role-physical,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions
  • Daprodustat vs rhEPO · MMRM · p = 0.1674 · Ls mean difference: 0.39 · 95% CI -0.40 to 1.19Role-physical,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, dialysis type, region,Baseline value and Baseline value by time and treatment by time interactions
  • Daprodustat vs rhEPO · MMRM · p = 0.6585 · Ls mean difference: -0.14 · 95% CI -0.82 to 0.54Social fun, Week 8: Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.0293 · Ls mean difference: 0.69 · 95% CI -0.03 to 1.40Social fun, Week 12: Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.2057 · Ls mean difference: 0.33 · 95% CI -0.45 to 1.11Social fun, Week 28: Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.4849 · Ls mean difference: 0.02 · 95% CI -0.86 to 0.90Social fun, Week 52: Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-Treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-Treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatrhEPO
Week 8, n=982,936-0.23 ± 0.219-0.26 ± 0.224
Week 12, n=990,943-0.17 ± 0.227-0.51 ± 0.232
Week 28, n=836,819-0.79 ± 0.242-1.03 ± 0.245
Week 52, n=729,707-1.19 ± 0.268-1.04 ± 0.272
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.4621 · Ls mean difference: 0.03 · 95% CI -0.58 to 0.64Week 8: Model was fitted from Baseline up to Week 52 and model adjusted Week 8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.1439 · Ls mean difference: 0.35 · 95% CI -0.29 to 0.98Week 12: Model was fitted from Baseline up to Week 52 and model adjusted Week 12 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.2392 · Ls mean difference: 0.24 · 95% CI -0.43 to 0.92Week 28: Model was fitted from Baseline up to Week 52 and model adjusted Week 28 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.6545 · Ls mean difference: -0.15 · 95% CI -0.90 to 0.60Week 52: Model was fitted from Baseline up to Week 52 and model adjusted Week 52 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-Treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-Treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatrhEPO
Week 8, n=982,9360.48 ± 0.237-0.16 ± 0.243
Week 12, n=990,9430.11 ± 0.240-0.45 ± 0.246
Week 28, n=836,819-0.20 ± 0.273-0.97 ± 0.277
Week 52, n=729,707-0.61 ± 0.291-1.19 ± 0.296
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.0290 · Ls mean difference: 0.64 · 95% CI -0.02 to 1.31Week 8: Model was fitted from Baseline up to Week 52 and model adjusted Week 8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.0509 · Ls mean difference: 0.56 · 95% CI -0.11 to 1.24Week 12: Model was fitted from Baseline up to Week 52 and model adjusted Week 12 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.0237 · Ls mean difference: 0.77 · 95% CI 0.01 to 1.53Week 28: Model was fitted from Baseline up to Week 52 and model adjusted Week 28 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.0828 · Ls mean difference: 0.58 · 95% CI -0.24 to 1.39Week 52: Model was fitted from Baseline up to Week 52 and model adjusted Week 52 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-Treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52

EQ-5D-5L is self-assessment questionnaire,consisting of 5 items covering 5 dimensions (mobility,self care,usual activities,pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health state). Change from Baseline was calculated as on-treatment visit value-Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.

Time frame:
Baseline (Pre-dose on Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-Treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52
Scores on a scaleDaprodustatrhEPO
Change From Baseline in On-Treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52-0.0198 ± 0.01179-0.0201 ± 0.01187
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.4939 · Ls mean difference: 0.0003 · 95% CI -0.0326 to 0.0331MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-Treatment EuroQol Visual Analogue Scale (EQ-VAS) at Week 52

The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst health one can imagine and 100 represents the best health one can imagine. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-Treatment EuroQol Visual Analogue Scale (EQ-VAS) at Week 52
Scores on a scaleDaprodustatrhEPO
Change From Baseline in On-Treatment EuroQol Visual Analogue Scale (EQ-VAS) at Week 52-1.0 ± 0.860.8 ± 0.87
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.9292 · Ls mean difference: -1.8 · 95% CI -4.2 to 0.6MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-Treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52

The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated worse outcome. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-Treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatrhEPO
Week 8, n=1102,1064-0.03 ± 0.0240.02 ± 0.025
Week 12, n=1102,10730.02 ± 0.0250.06 ± 0.025
Week 28, n=934,9330.04 ± 0.0270.08 ± 0.027
Week 52, n=826,8140.06 ± 0.0290.11 ± 0.030
Statistical analysis
  • Daprodustat vs rhEPO · MMRM · p = 0.0428 · Ls mean difference: -0.06 · 95% CI -0.13 to 0.01Week 8: Model was fitted from Baseline up to Week 52 and model adjusted Week 8 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.1155 · Ls mean difference: -0.04 · 95% CI -0.11 to 0.03Week 12: Model was fitted from Baseline up to Week 52 and model adjusted Week 12 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.1426 · Ls mean difference: -0.04 · 95% CI -0.12 to 0.03Week 28: Model was fitted from Baseline up to Week 52 and model adjusted Week 28 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs rhEPO · MMRM · p = 0.1152 · Ls mean difference: -0.05 · 95% CI -0.13 to 0.03Week 52: Model was fitted from Baseline up to Week 52 and model adjusted Week 52 data has been presented, with factors for treatment, time, dialysis type, region, Baseline value and Baseline value by time and treatment by time interactions.

Adverse events

Collected over All-cause mortality, treatment emergent serious adverse events (TESAEs) and non-serious treatment emergent adverse events (TEAEs) were collected up to 3.9 person-years for CV follow-up time period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daprodustat294/1,487 (19.8%)773/1,482 (52.2%)830/1,482 (56%)
rhEPO300/1,477 (20.3%)748/1,474 (50.7%)827/1,474 (56.1%)
Most frequent serious events
Showing 10 of 888
Most frequent serious events
EventDaprodustatrhEPO
PneumoniaInfections and infestations86/148281/1474
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications36/148257/1474
Fluid overloadMetabolism and nutrition disorders42/148245/1474
AnaemiaBlood and lymphatic system disorders26/148241/1474
SepsisInfections and infestations29/148237/1474
HyperkalaemiaMetabolism and nutrition disorders19/148236/1474
Atrial fibrillationCardiac disorders23/148235/1474
Acute myocardial infarctionCardiac disorders30/148231/1474
PeritonitisInfections and infestations31/148224/1474
COVID-19Infections and infestations22/148222/1474
Most frequent other events
Showing 10 of 19
Most frequent other events
EventDaprodustatrhEPO
HypertensionVascular disorders235/1482232/1474
DiarrhoeaGastrointestinal disorders161/1482176/1474
HeadacheNervous system disorders115/1482139/1474
Dialysis hypotensionVascular disorders135/1482105/1474
HypotensionVascular disorders115/148292/1474
NasopharyngitisInfections and infestations113/1482104/1474
ArthralgiaMusculoskeletal and connective tissue disorders101/1482111/1474
CoughRespiratory, thoracic and mediastinal disorders101/1482101/1474
Upper respiratory tract infectionInfections and infestations99/148292/1474
BronchitisInfections and infestations87/148297/1474

Baseline characteristics

All Randomized (Intent-to-treat \[ITT\]) Population comprised of all randomized participants. Participants were analyzed according to the treatment to which they were randomized.

Age, Continuous
Age, Continuous(Years)DaprodustatrhEPOTotal
Mean57.2 ± 14.2957.3 ± 14.6557.2 ± 14.47
Sex: Female, Male
Sex: Female, Male(Participants)DaprodustatrhEPOTotal
Female6366301266
Male8518471698
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DaprodustatrhEPOTotal
American Indian or Alaskan Native193251
Asian - Central/South Asian Heritage364682
Asian - East Asian Heritage9786183
Asian - Japanese Heritage336
Asian - South East Asian Heritage404585
Black or African American228233461
Native Hawaiian or Other Pacific Islander262551
White - Arabic/North African Heritage81422
White - White/Caucasian/European Heritage9879681955
Mixed Asian Race011
Mixed Race432467
08

Study locations

462 sites
  • GSK Investigational Site
    Huntsville, Alabama 35805, United States
  • GSK Investigational Site
    Pine Bluff, Arkansas 71603, United States
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Bakersfield, California 93308, United States
  • GSK Investigational Site
    Bakersfield, California 93309, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Cerritos, California 90703, United States
  • GSK Investigational Site
    Chula Vista, California 91910, United States
  • GSK Investigational Site
    El Centro, California 92243, United States
  • GSK Investigational Site
    Escondido, California 92025, United States
  • GSK Investigational Site
    Fairfield, California 94534, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Glendale, California 91205, United States
  • GSK Investigational Site
    Granada Hills, California 91344, United States
  • GSK Investigational Site
    Hacienda Heights, California 91745, United States
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    La Palma, California 90623, United States
  • GSK Investigational Site
    Lakewood, California 90712, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Long Beach, California 90807, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90022, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Lynwood, California 60262, United States
  • GSK Investigational Site
    Montebello, California 90640, United States
  • GSK Investigational Site
    Monterey Park, California 91754, United States
  • GSK Investigational Site
    Moreno Valley, California 92553, United States
  • GSK Investigational Site
    Norco, California 92860, United States
  • GSK Investigational Site
    Northridge, California 91324, United States
  • GSK Investigational Site
    Ontario, California 91762, United States
  • GSK Investigational Site
    Riverside, California 92501, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    San Diego, California 92111, United States
  • GSK Investigational Site
    San Luis Obispo, California 93405, United States
  • GSK Investigational Site
    Santa Clarita, California 91387, United States
  • GSK Investigational Site
    Simi Valley, California 93065-091, United States
  • GSK Investigational Site
    Tarzana, California 91356, United States
  • GSK Investigational Site
    Whittier, California 90602, United States
  • GSK Investigational Site
    Whittier, California 90603, United States
  • GSK Investigational Site
    Yorba Linda, California 92886, United States
  • GSK Investigational Site
    Middlebury, Connecticut 06762, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Hollywood, Florida 33024, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Lauderdale Lakes, Florida 33313, United States
  • GSK Investigational Site
    Miami Gardens, Florida 33169, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33143, United States
  • GSK Investigational Site
    Miami, Florida 33150, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Ocala, Florida 34471, United States
  • GSK Investigational Site
    Port Charlotte, Florida 33952, United States
  • GSK Investigational Site
    Spring Hill, Florida 34608, United States
  • GSK Investigational Site
    Winter Park, Florida 32789, United States
  • GSK Investigational Site
    Augusta, Georgia 30904, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Meridian, Idaho 83642, United States
  • GSK Investigational Site
    Crystal Lake, Illinois 60014, United States
  • GSK Investigational Site
    Fort Wayne, Indiana 46804, United States
  • GSK Investigational Site
    Jeffersonville, Indiana 47130, United States
  • GSK Investigational Site
    Merrillville, Indiana 46410, United States
  • GSK Investigational Site
    Michigan City, Indiana 46360, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70836, United States
  • GSK Investigational Site
    Greenbelt, Maryland 20770, United States
  • GSK Investigational Site
    Takoma Park, Maryland 20912-6385, United States
  • GSK Investigational Site
    Kalamazoo, Michigan 49007, United States
  • GSK Investigational Site
    Pontiac, Michigan 48341, United States
  • GSK Investigational Site
    Roseville, Michigan 48066, United States
  • GSK Investigational Site
    Gulfport, Mississippi 39501, United States
  • GSK Investigational Site
    Tupelo, Mississippi 38801, United States
  • GSK Investigational Site
    Florissant, Missouri 63033, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89102, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89107, United States
  • GSK Investigational Site
    Portsmouth, New Hampshire 3801, United States
  • GSK Investigational Site
    Gallup, New Mexico 87301, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    Flushing, New York 11355, United States
  • GSK Investigational Site
    Mineola, New York 11501, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Ridgewood, New York 11385, United States
  • GSK Investigational Site
    Yonkers, New York 10710, United States
  • GSK Investigational Site
    Asheville, North Carolina 28801, United States
  • GSK Investigational Site
    Clyde, North Carolina 28721, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27517, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45206, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45220, United States

Showing the first 100 of 462 sites across 35 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Blackorby A, Cizman B, Cobitz AR, Davies R, Dole J, Kler L, Meadowcroft AM, Zhu X, McMurray JJV; ASCEND-D Study Group. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 Dec 16;385(25):2325-2335. doi: 10.1056/NEJMoa2113379. Epub 2021 Nov 5. PubMed 34739194 ↗
  • Singh AK, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, Jha V, Johansen KL, Lopes RD, Kler L, Macdougall IC, McMurray JJV, Meadowcroft AM, Obrador GT, Perkovic V, Solomon S, Wanner C, Waikar SS, Wheeler DC, Wiecek A. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 Apr 25;37(5):960-972. doi: 10.1093/ndt/gfab065. PubMed 33744933 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Nov 2020, 49 months.

Results were first posted in Dec 2021, 1 year after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 49 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2016
First posted
Aug 25, 2016
StartActual
Sep 28, 2016
Primary completionActual
Nov 9, 2020
CompletionActual
Nov 9, 2020
Results first posted
Dec 3, 2021
Last update
Dec 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02879305
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 25, 2016
Start date
Sep 28, 2016
Primary completion
Nov 9, 2020
Completion
Nov 9, 2020
Results posted
Dec 3, 2021
Last update
Dec 3, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion